Stemline Therap Company Profile
✉ Email this page to a colleague
What is the competitive landscape for STEMLINE THERAP, and when can generic versions of STEMLINE THERAP drugs launch?
STEMLINE THERAP has one approved drug.
There are eight US patents protecting STEMLINE THERAP drugs.
There are one hundred and nine patent family members on STEMLINE THERAP drugs in twenty-six countries and seven supplementary protection certificates in seven countries.
Summary for Stemline Therap
| International Patents: | 109 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Stemline Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 10,385,008 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 11,779,552 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 8,399,520 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | 11,819,480 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 10,071,066 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Stemline Therap Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 11201708861V | ⤷ Subscribe |
| China | 113750091 | ⤷ Subscribe |
| Japan | 6926066 | ⤷ Subscribe |
| Spain | 2939940 | ⤷ Subscribe |
| European Patent Office | 4035664 | ⤷ Subscribe |
| Poland | 3565542 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Stemline Therap Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3122426 | 3/2024 | Austria | ⤷ Subscribe | PRODUCT NAME: ELACESTRANT ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1757 (MITTEILUNG) 20230918 |
| 3122426 | 122024000013 | Germany | ⤷ Subscribe | PRODUCT NAME: ELACESTRANT ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1757 20230915 |
| 3122426 | PA2024504 | Lithuania | ⤷ Subscribe | PRODUCT NAME: ELACESTRANTAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1757 20230915 |
| 3122426 | 2024C/505 | Belgium | ⤷ Subscribe | PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918 |
| 3122426 | 301263 | Netherlands | ⤷ Subscribe | PRODUCT NAME: ELACESTRANT, DESGEWENST IN DE VORM VAN ELACESTRANTDIHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/23/1757 20230918 |
| 3122426 | CA 2024 00007 | Denmark | ⤷ Subscribe | PRODUCT NAME: ELACESTRANT OR A SALT THEREOF; REG. NO/DATE: EU/1/23/1757 20230918 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
